ONO—802阴道给药抗早孕50例临床效果观察

本文报告了停经56天以内的早孕妇女应用ONO-802阴道栓剂抗早孕的临床观察及效果。50例早孕妇女住院观察24小时,阴道投药1枚(1mg/枚),5枚为一疗程。用药后1周、2周、4～6周门诊随访,复查尿HCG、血红蛋白。在第二周随访时判断用药效果。临床结果:总有效率82%,其中完全流产76%,不全流产6%,失败率18%。ONO-802使用方便,副反应轻,是深受广大妇女欢迎的一种非手术终止妊娠的方法。本项试验结果通过与国内PG 联合用药的结果和研究资料对比,ONO-802如果能与丙睾、R2323、天花粉等联合应用,将会提高其抗早孕的有效率。     

A comparative study of measurement of arterial blood pressure using HEM-802F and arterial cannulation

Finger arterial blood pressures determined by a newly developed sphygmomanometer, HEM-802F, were compared with arterial pressure obtained from direct measurement of the radial artery. An excellent correlation was found between the two methods (systolic: r = 0.93, diastolic: r = 0.91), although there was a large variability among individual subjects. The range of differences between them are from +32 to –13mmHg for systolic and +15 to –25mmHg for diastolic blood pressure measurement. HEM-802F underestimated systolic pressure (–4.0mmHg) and overestimated diastolic pressure (+6.7mmHg), compared with intra-arterial readings.The HEM-802F was useful for the non-invasive arterial pressure monitoring during general anesthesia.(Shigemi K, Takahashi H, Hashimoto S et al.: A comparative study of measurement of arterial blood pressure using HEM-802F and arterial cannulation. J Anesth 4: 91–93, 1990)     

Magnetic resonance spectroscopy and molecular studies in ornithine transcarbamylase deficiency novel mutation c.802A>G in exon 8 (p.Met268Val)

Ornithine transcarbamylase (OTC) deficiency, an X-linked, semidominant disorder, is the most common inherited defect in ureagenesis, resulting in hyperammonaemia type II. The OTC gene, localised on chromosome X, has been mapped to band Xp21.1, proximate to the Duchenne muscular dystrophy (DMD) gene. More than 350 different mutations, including missense, nonsense, splice-site changes, small deletions or insertions and gross deletions, have been described so far. Almost all mutations in consensus splicing sites confer a neonatal phenotype. Most mutations in the OTC gene are ‘private’ and are distributed throughout the gene with a paucity of mutation in the sequence encoding the leader peptide (exon 1 and beginning of exon 2) and in exon 7. They have familial origin or occur de novo. Even with sequencing of the entire reading frame and exon/intron boundaries, only about 80% of the mutations are detected in patients with proven OTC deficiency. The remainder probably occur within the introns or in regulatory domains. The authors present a 4-year-old boy with the unreported missense mutation c.802A>G. The nucleotide transition leads to amino acid substitution Met to Val at codon 268 of the OTC protein.     

miR-802在原发性肝细胞癌中的表达及意义

[目的]检测微小RNA(miR)-802在原发性肝细胞癌(hepatocellular carcinoma,HCC)组织与细胞中的表达水平,分析miR-802在HCC中的临床意义。[方法]采用qRT-PCR检测HCC癌组织与癌旁组织中mi R-802的表达水平,及Hep3B、HCCLM3与HL-7702细胞的表达水平。分析miR-802表达水平与HCC临床病理特征的关系。采用Kaplan-Meier方法计算生存曲线,以Log-rank检验评估miR-802表达水平与HCC预后的关系。通过Cox比例风险回归模型单因素和多因素分析评估HCC的预后指标。[结果] HCC癌组织中miR-802的表达水平显著低于癌旁组织(P<0.05),且Hep3B、HCCLM3细胞中mi R-802的表达水平亦显著低于HL-7702细胞(P<0.05)。Ⅲ+Ⅳ期癌组织中miR-802的表达水平低于Ⅰ+Ⅱ期癌组织(P<0.05),血管转移患者癌组织中miR-802的表达水平低于非血管转移患者癌组织(P<0.05)。mi R-802低表达组患者的5年生存率显著低于高表达组(P<0.05)。单因素分析显示,低表达mi R-802、高TNM分期及阳性血管转移是HCC患者预后不良的预测指标(P<0.05)。多因素分析显示,低表达miR-802是HCC患者预后不良的唯一独立预测指标(P<0.05)。[结论] HCC组织和细胞中miR-802表达下调,低表达miR-802是HCC患者预后不良的独立预测指标。     

Structural elucidation of the Rifaximin Ph. Eur. Impurity H

Rifaximin, a semisynthetic, rifamycin-based non-systemic antibiotic is used in the treatment of acute and chronic gastrointestinal disorders. The aim of this study was the elucidation of the molecular structure of the 802 Dalton impurity which was found in Rifaximin industrial batches and reported with an erroneous structure in European Pharmacopoeia 6.5 (2009) [7] monograph as Rifaximin Impurity H. This impurity was isolated from Rifaximin by preparative HPLC and purified by column chromatography. The molecular structure was evidenced by means of ¹H and ¹³C NMR spectroscopy, mass spectrometry and FT-IR.     

miR-802靶向Hnf1B抑制胰岛素分泌的作用研究

探究miR-802对于胰岛β细胞分泌胰岛素的影响及其作用机制。利用miR-802类似物及miR-802抑制剂分别在胰岛原代细胞及Min6细胞过表达或敲降miR-802；采用ELISA法检测miR-802对胰岛素分泌的影响；通过miRNA靶基因数据库预测、荧光素酶报告法和Western blot法确证miR-802的靶基因；最后开展功能回复实验阐明miR-802调控胰岛β细胞分泌胰岛素的作用机制。结果表明:在胰岛原代细胞和Min6细胞中过表达miR-802能抑制胰岛β细胞分泌胰岛素；qPCR和Western blot实验证明miR-802通过抑制靶基因肝细胞核因子1B(hepatocyte nuclear factor 1β，Hnf1B)的转录和翻译，从而抑制胰岛素的分泌。     

miR-802及其靶基因ROS1在口腔鳞状细胞癌中的表达及临床意义

目的:研究miRNA-802（miR-802）及其靶基因ROS1在口腔鳞状细胞癌（oral squamous cell carcinoma,OSCC）中的表达及潜在临床意义。方法:收集原发OSCC组织及相应癌旁组织标本23例;荧光定量PCR检测各标本中miR-802及ROS1的表达;免疫组织化学检测各标本中ROS1的表达;结合患者临床病理资料,分析miR-802及ROS1在OSCC发生发展中可能的临床意义。结果:与癌旁组织相比较,OSCC组织中miR-802的表达显著降低（P<0.001）,而ROS1的表达显著升高（P<0.01）;相关性分析显示miR-802与ROS1在OSCC中的表达呈显著负相关（r=-0.746,P<0.0001）;miR-802与ROS1的表达水平与患者年龄,性别、肿瘤大小等临床病理特征无显著相关性,而与TNM分期及淋巴结转移有显著相关性（P<0.05）。结论:miR-802通过介导其靶基因ROS1参与调控口腔鳞状癌的发生发展过程。